	US 12,391,659 B2
	Benzothiazole and related compounds
Stella Sarraf, Beverly Hills, CA (US); Vincent F. Simmon, San Diego, CA (US); and Gerald F. Swiss, San Diego, CA (US)
Assigned to Spinogenix, Inc., Los Angeles, CA (US)
Filed by Spinogenix, Inc., San Diego, CA (US)
Filed on Aug. 2, 2021, as Appl. No. 17/392,036.
Application 17/392,036 is a continuation of application No. 16/635,872, granted, now 11,117,878, previously published as PCT/US2018/044852, filed on Aug. 1, 2018.
Claims priority of provisional application 62/540,311, filed on Aug. 2, 2017.
Prior Publication US 2022/0017477 A1, Jan. 20, 2022
Int. Cl. C07D 277/66 (2006.01); A61P 25/28 (2006.01)

CPC C07D 277/66 (2013.01) [A61P 25/28 (2018.01)]

18 Claims

1. A pharmaceutical composition comprising a compound according to Formula VII:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

subscripts n and p are each independently selected from 0, 1, or 2;

subscript q is an integer selected from 2, 3, and 5-8; and

each R¹and R²are independently selected from the group consisting of halo, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, acyl, acylamino, aminocarbonyl, aminosulfonyl, amino, substituted amino, aryl, substituted aryl, carboxyl, carboxyl esters, cyano, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, hydroxyl, sulfonyl, substituted sulfonyl, thiol, thioalkyl, and nitro,

and one or more pharmaceutically acceptable excipients.